



ADVANCES IN DIAGNOSTICS AND IMMUNOTHERAPEUTICS FOR NEURODEGENERATIVE DISEASES

Editors:

Anuradha Mishra

Preeti Bajpai

Tarique Mahmood Ansari

Bentham Books

Regulating Nerve Network	152
Neurotransmitter Receptors on Microglia	152
EPIGENETIC REGULATION OF MICROGLIA	153
Histone Acetylation	153
Histone Methylation	154
DNA Methylation	156
Epigenetic Crosstalk	156
CONCLUSION	157
REFERENCES	157
CHAPTER 8 EPIGENETICS AS DIAGNOSTIC AND THERAPEUTIC TOOL IN	
NEURODEGENERATIVE DISORDERS	162
<i>Rufaida Wasim, Tarique Mahmood, Farogh Ahsan, Aditya Singh and Asad Ahmad</i>	
INTRODUCTION	162
EARLY DIAGNOSIS AND TREATMENT	164
NEURODEGENERATIVE DISORDERS AND EPIGENETIC ALTERATION	164
POTENTIAL EPIGENETIC THERAPEUTIC INTERVENTION TARGETS	166
Inhibitors of DNA Methylation and DNA Methyltransferases (DNMT)	166
Histone Acetylation and Histone Deacetylases (HDAC) Inhibitors	167
NEURODEGENERATIVE DISORDERS TREATMENT	169
Alzheimer's Disease	169
Parkinson's Disease	170
Huntington's Disease	171
CONCLUSION	172
ACKNOWLEDGMENT	172
REFERENCES	172
CHAPTER 9 CURRENT THERAPEUTIC OPTIONS AND REPURPOSED DRUGS FOR	
NEURODEGENERATION	177
<i>Suneela Dhaneshwar, Mohammad Aadil Bhat, Anuradha Singh and Supriya Roy</i>	
INTRODUCTION	177
Drug Repurposing	178
ALZHEIMER'S DISEASE (AD)	179
DRUG REPURPOSING FOR AD	180
Anti-cancer Agents	180
<i>Epidermal Growth Factor Receptor Inhibitors (EGFRI)</i>	180
<i>Tyrosine Kinase Inhibitors</i>	181
Retinoid X Receptor (RXR) Agonists	183
Miscellaneous Drugs	183
Antidiabetic Drugs	184
<i>Hypoglycaemic Agents</i>	184
<i>Anti-hyperglycaemic Drugs</i>	185
Antihypertensive Drugs	186
Antiepileptic Drugs	187
Phosphodiesterase-5 Inhibitors	187
PARKINSON'S DISEASE (PD)	188
Drug Repurposing for PD	189
<i>Exenatide</i>	189
<i>Nilotinib</i>	189
<i>Terazosin</i>	190
<i>Simvastatin</i>	190
<i>Ursodeoxycholic Acid</i>	191

Epigenetics as Diagnostic and Therapeutic Tool in Neurodegenerative Disorders

Rufaida Wasim^{1,*}, Tarique Mahmood¹, Farogh Ahsan¹, Aditya Singh¹ and Asad Ahmad¹

¹ Department of Pharmacy, Integral University, Lucknow, India-226026

Abstract: Epigenetics is a field that is concerned with the investigation of heritable modifications in gene expression that transpire without DNA sequence alterations, thereby establishing a connection between the genome and its surroundings. Epigenetics simply analyzes gene expression amendment beyond variation to the DNA sequence. The gradual accumulation of epigenetic changes over the course of an individual's life span may contribute to neurodegeneration. This chapter deals with epigenetic alteration, which affects the progress of neurodegeneration with age. Epigenetic regulation, encompassing DNA methylation and histone modification, has been implicated in the anomalous alterations in gene expression that occur during the progression of neurodegeneration. The concept of epigenetics is useful to synthesize novel medications to target these disorders. In recent times, a plethora of epigenetics-based medications have been developed for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. Due to a major lack of early screening processes that allow therapeutic agents to be distributed to afflicted neurons paramount to cell death, many neurological conditions have severely restricted options for treatment. Significant progress has been seen in neurodegenerative disease biomarkers. These biomarkers have been unfortunate, due to substantial disparities amidst the tissues acclimated to source biomarkers and biomarkers of disease. Neurodegeneration may be exacerbated by epigenetic changes that develop gradually. Epigenetic biomarkers could aid in the diagnosis, and monitoring, of neurodegenerative diseases.

Keywords: Diagnosis, Epigenetics, Neurodegenerative disorders, Treatment.

INTRODUCTION

Neurodegenerative disorders pose an enormous challenge and represent some of the most severe health problems that societies will face around the world. These are progressive and incurable conditions, which arise from the continuous degene-

* Corresponding author Rufaida Wasim: Department of Pharmacy, Integral University, Lucknow, India;
E-mail: rufaidawasim08@gmail.com